ATS is pleased to announce Beta-release of a wide array of targeted toxins for use in eliminating specific cell types. This Beta-Testing Program will make new conjugates available to our customers sooner.
Each of the Beta products has had:
- Saporin activity confirmed,
- Peptide sequences published/confirmed, and/or
- Antibody binding specificity published/confirmed.
Beta Products have not been characterized or reported in scientific literature. This provides researchers with special Beta-pricing and the opportunity to be the first to publish using the material. The researcher who first publishes data will receive a $500 credit for use on ATS products.
Contact ATS to discuss your project.
Data submitted will be reviewed by the scientific team at ATS. If data is sufficient to prove specific activity of Beta material in either in vivo or in vitro conditions, the Beta Tester will be informed and product credit will be awarded to the first Beta Tester to publish.
Beta Products now available as catalog items:
Anti-CD105-SAP (Cat. #IT-80) previously BETA-015
Anti-CD44-SAP (Cat. #IT-72) previously BETA-004
Anti-PD-L1-SAP (Cat. #IT-45) previously BETA-014
Chlorotoxin-SAP (Cat. #IT-86) previously BETA-010
Ex4-SAP (GLP-1-SAP) (Cat. #IT-90) previously BETA-009
MOA-SAP (Cat. #IT-92) previously BETA-013
Orexin-B-SAP (Cat. #IT-20) previously BETA-031
PACAP-SAP (Cat. #IT-84) previously BETA-029